, both caused by loss-of-function mutations of the CaR gene, and those that occur as a consequence of gain-of function mutations of the CaR, e.g., autosomal dominant hypocalcemia (ADH) and Bartter syndrome (BS) type V [3] [4] [5] . However, the CaR is also a factor in other more common pathologies that include chronic kidney disease 6 , cancer 7 , cardiovascular pathologies [8] [9] [10] [11] , and Alzheimer's disease 12 . For a complete survey of CaR's function in molecular physiology and pathology, readers are referred to some of the many recent reviews on the topic 13 .
We will first address when and how Ca 2+ ext , the primary ligand for the CaR, changes in tissue spaces. Ca 2+ is, however, just one of the many activators of this fascinating receptor; the CaR is "built" to interact with a dizzying array of other orthosteric agonists and also allosteric modulators that influence the receptor's response to calcium ions (Table 1) . These endogenous ligands activate multiple intracellular signaling pathways, often in the same cell type (Figure 1 ). However, the CaR can discriminate between its ligands to preferentially activate a particular subset of signaling pathways at the exclusion of others through the phenomenon known as biased agonism. In addition, CaR signaling can be dynamically regulated through agonist-dependent trafficking of intracellular receptors to alter the net amount of the receptor at the plasma membrane. We will address how certain ligands act as "pharmacoperones" to shepherd the receptor to the cell surface. All of these factors serve to fine-tune the activity of the receptor. Finally, we discuss the incredible potential of this newfound information to aid in the design of novel, smarter, drugs able to rescue mutated receptor mislocalization and function, and bias CaR-mediated signaling towards particular pathways. fluctuations is thought to represent an autocrine/paracrine form of cell-to-cell communication. Pharmacological agents directed at the CaR therefore work upon a complex backdrop of changing external [Ca 2+ ]. This has the potential to markedly affect the way in which a drug (particularly those in the class of the allosteric modulators) acts on the receptor in any given moment. Knowledge about these local fluctuations in calcium remains, arguably, among the most significant barriers to fully understanding CaR pharmacology in vivo. -sensitive resins with affinities in the μM and mM range. In addition, it is possible to record Ca 2+ ext changes for hours without technical drawbacks such as the bleaching of fluorescent indicators. However, this approach requires a high level of patience and expertise and samples only one small region of the tissue, so it is not amenable to high-throughput measurements. Moreover, it is difficult to execute in many tissue types. This is an arena in which further developments would be welcome. . When GPCRs are coupled to multiple G-proteins in the same cell type, as is the CaR, the old dogma hypothesized that they activate each of the downstream signals equally, without preference for any one pathway 58-61 .
Extracellular

Origins of extracellular
In the past few years, several studies have painted a more complex scenario, in which receptors, existing in multiple active states, can specifically trigger selected pathways at the exclusion of others
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. This will depend not only on the signaling toolkit of the cell in which they are expressed but also on numerous other factors 63 , such as the localization of the GPCRs, the duration of stimulus for GPCRs working in non-equilibrium conditions, the downstream signaling protein level (i.e. involvement of different effectors able to shape diverse Ca 2+ and cAMP microdomains and kinetics), and the specific agonist/modulator activating the receptor 64 . Also, it has been shown that GPCRs traffic through subcellular compartments such as the nucleus 65 , mitochondria 66 , and endosomes 67, 68 , where they are capable of initiating specific signaling pathways.
In this context, pharmacological studies have shown that ligands are able to bias the signaling of their GPCRs towards specific intracellular responses and/or are capable of crossing cell membranes, thus activating or rescuing intracellular GPCRs (by acting as molecular chaperones) 69 . The development of new technologies, such as microscopy techniques and probes to follow receptor trafficking 63, 70 and to assess in real time subcellular signaling dynamics 71,72 as well as biased signaling 73 , has been essential for such advances and will certainly continue to promote novel and exciting discoveries in this field.
The "anti-conformist" extracellular calcium-sensing receptor traffics to the plasma membrane via a novel route: agonist-driven insertional signaling
In the classical life cycle of GPCRs, the newly synthesized receptor is inserted into the endoplasmic reticulum and, after folding, is transported through the cis-Golgi/Golgi/trans-Golgi, where it goes through further post-translational changes. Then the mature protein, packaged in small vesicles, undergoes insertion into the cell membrane. If misfolded, the protein is degraded by the proteasome. Upon binding, ligands stabilize preferred conformational state(s) of the receptor that initiate intracellular signaling. The process is terminated via receptor internalization mediated by GPCR kinase (GRK) phosphorylation and β-arrestin(s) recruitment 74 . The internalized receptor can be degraded by the lysosome or recycled to the cell membrane. Importantly, both β-arrestin and internalized receptors can initiate signaling.
It is well established that the fine balance among maturation, internalization, recycling, and degradation can influence the net amount of cell surface receptor level and thus represents a mechanism for the cell to regulate receptor sensitization and modulate the strength of signal transduction 75 . The intensity of signaling is thus related to the quantity of GPCRs expressed on the cell surface and accessible for ligand stimulation. This is also true for the CaR, as recently demonstrated by Brennan and colleagues 76 .
Relevant advancements in the knowledge of the key players involved in CaR biosynthesis and trafficking have been achieved in the last ten years [77] [78] [79] [80] [81] . Both early and recent studies have highlighted that two hallmarks of the CaR are the negligible functional desensitization and the existence of a significant amount of CaR in intracellular membranes. Early studies indicated, both by western blotting or immunohistochemistry 14, 82, 83 , that CaR immunoreactivity reflected a predominantly intracellular, coreglycosylated form. It is now becoming clear that such an observation is not a mere artifact but is strictly related, and even of functional importance, to the complex and mutual interaction between CaR trafficking and signaling. In fact, both minimal desensitization and high levels of intracellular CaR can be explained by the model of agonist-driven insertional signaling (ADIS) 78, 84 .
The process of ADIS depends upon the regulated release of mature CaR proteins from a large intracellular pool located in the endoplasmic reticulum and Golgi/post-Golgi vesicles. The rate of CaR plasma membrane insertion increases as a function of the concentration of CaR agonists and/or allosteric modulators, while the receptor already at the plasma membrane undergoes constitutive endocytosis without substantial recycling. Importantly, and predictably, in this model, CaR signaling can be dynamically regulated by the trafficking of intracellular CaR to the plasma membrane through an agonist-dependent modulation of the net amount of CaR at the plasma membrane. This has implications in both health and disease 85 .
New insights into the mechanisms underlying the therapeutic potential of allosteric modulators of the extracellular calcium-sensing receptor
As summarized in Interestingly, a number of recent reports have shown that allosteric modulators can act as pharmacoperones. Pharmacoperones (or pharmacological chaperones or pharmacochaperones) are membrane-permeant ligands (agonists, antagonists, or allosteric modulators) that reach the misfolded protein at the site of its biosynthesis and trafficking (most frequently the endoplasmic reticulum) and, by stabilizing the receptor structure, rescue the protein to the cell surface 69 .
Breitwieser's group has published a number of interesting papers highlighting the capability of CaR allosteric modulators to function as pharmacoperones [86] [87] [88] . While an early study reported the synergistic effect of acute treatment with L-phenylalanine and NPS R-467 on CaRs with inactivating mutations 89 , Breitwieser and colleagues first showed that overnight treatment of HEK293 cells expressing loss-of-function mutant CaRs with the calcimimetic NPS R-568 rescued plasma membrane expression and signaling in 50% of the mutations examined 86, 87 . Similar results were obtained by other groups, although the authors did not investigate the cell surface expression of CaR after NPS R-568-mediated signal rescue 90, 91 . Interestingly, the capability of the calcimimetic NPS R-568 to rescue CaR activation without altering the cell surface expression of the mutant proteins was shown in a recent study 92 , suggesting a mutant-specific effect of this drug as a pharmacoperone.
Relevant findings in this area have also been provided by Leach and colleagues 93, 94 . They showed that calcimimetics, including the only calcimimetic approved in the clinic (cinacalcet), effectively rescue trafficking and signaling of CaR mutants exhibiting a loss of cell surface expression. They also found that the calcilytic NPS 2143 effectively promotes trafficking of CaR mutants to the cell membrane while negatively modulating CaR signaling 93, 95 . This is in contrast to other studies with NPS 2143 showing a reduced 86 or unchanged 92 effect on the expression of diverse CaR gain-of-function mutants, suggesting that a mutant-specific pharmacoperone effect also exists for NPS 2143.
The potential of calcilytics for patients with activating CaR mutations has been further examined in vitro 96 . More recently, the new quinazolinone-derived calcilytics were shown to be effective in attenuating enhanced calcium signaling in mutations causing BS and ADH
97
. NPS 2143 was also found to correct signaling defects in HEK293 cells transfected with Gα11-mutated proteins causing ADH2 and uveal melanoma 98 . Very interestingly, the effectiveness of both old (i.e. NPS 2143) 99 and new (i.e. JTT-305/MK-5442) 100 calcilytics was recently assessed in vivo in mouse models harboring ADH gain-of-function CaR mutations.
Biased signaling at the extracellular calcium-sensing receptor
Recent reports suggest that the therapeutic potential of new classes of CaR modulators, as well as the pathophysiological role of endogenous agonists, could be further improved by exploiting the phenomenon of biased signaling 11 . Biased signaling (also known as ligand-directed signaling, stimulus bias, biased agonism, or functional selectivity) 62,101,102 represents a general, albeit only recently appreciated, signaling characteristic of GPCRs 58 . It refers to the ability of different ligands to stabilize distinct receptor conformations and preferentially direct GPCR signaling towards a specific set of pathways while excluding/reducing others.
This concept, while greatly complicating the scenario of GPCR signaling, opens up new perspectives in the design of smart and tissue-specific drugs 103 . The existence of ligand-and tissue-specific effects in the signaling pathways activated by the CaR, although not precisely quantified, is traceable in a vast number of papers published throughout the years. In fact, in many cases, biased signaling at the CaR might have been underestimated owing to the use of single assays for the evaluation of CaR signaling outputs (most commonly cytosolic calcium dynamics) or the low number of CaR agonists and modulators tested.
A peculiar case of biased signaling at the CaR was observed in response to an allosteric autoantibody isolated from a patient with acquired hypocalciuric hypocalcemia. The possibility of exploiting biased agonism at the CaR has been extensively explored by the group of Christopoulos and Leach 93, [114] [115] [116] . These authors analyzed the effect of calcimimetics and calcilytics on a number of CaR mutations 115 (reviewed in 95,103) , demonstrating that mutated CaR proteins can display altered signaling bias. Importantly, and as stated above, both cinacalcet and NPS 2143 were shown to effectively rescue mutants to the cell membrane, with a bias of both compounds toward the modulation of agonist-stimulated Ca 2+ mobilization 93 . There is no doubt that these results have relevant therapeutic potential.
To date, cinacalcet has been used for the treatment of hyperparathyroidism and to correct Ca 2+ ext in patients with loss-of-function CaR mutations. However, because of its hypocalcemic side effects, presumably due to CaR-mediated calcium-dependent calcitonin secretion from thyroid parafollicular C-cells 108 and potentiation of renal CaRs, its use has been restricted to patients with end-stage renal disease. Thus, a drug that suppresses PTH secretion without raising serum calcitonin would be therapeutically advantageous.
Potential clues towards the search for a calcimimetic with low/no effect on calcitonin was hinted at in a very recent paper 94 . In this work, the authors demonstrated that while phenylalkylamine calcimimetics were biased towards Ca 2+ mobilization and IP 1 accumulation (a stable metabolite of IP 3 ), R,R-calcimimetic B and AC-265347 biased CaR signaling towards pERK1/2 and IP 1 accumulation. This finding may explain the preference of R,Rcalcimimetic B and AC-265347 for the suppression of PTH release versus the stimulation of calcitonin secretion in vivo.
Structure-function relationships and future prospects
Recent work explored the structural requirements for bias and allostery mediated by old and new classes of positive and negative allosteric modulators of the CaR
116
. Further, Jenny Yang's lab has published several papers about the potential Ca 2+ binding sites and their relevance for related diseases [117] [118] [119] [120] [121] [122] [123] [124] . Recently, these authors solved the first high-resolution crystal structure of the ECD of human CaR bound with Mg
2+117
. Of note, a high-affinity tryptophan derivative was found in the crystal structure of the CaR that seems to play a role in potentiating the function of the receptor 117 . These studies represent important progress in the field, since they provide new insights into the structural basis of human diseases arising from CaR mutations. Ultimately, the subtle differences in modulator binding sites revealed by structural studies may be exploited to design drugs able to elicit distinct signaling outcomes and thus be effective on specific mutations (patient-specific drugs) and/or on tissue-specific signaling pathways (tissue-specific drugs).
In this scenario, a fundamental challenge for future research will be to set up methodological tools to validate these latest pharmacological advances in more physiologically relevant models, such as primary cells or animal models. It also remains to be seen how the functional effects of these drugs are altered in the complex landscape of changing [Ca 2+ ] in extracellular microdomains in vivo.
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